Pronto Diagnostics

What Pronto Diagnostics does

Pronto Diagnostics Ltd. is a privately held, founder-owned molecular diagnostics company headquartered at Kiryat Atidim in Tel Aviv, Israel. The company operates across four business lines: (1) development, manufacturing and marketing of its proprietary PRONTO® diagnostic kits based on ELISA technology for single nucleotide primer extension (CE certified); (2) operation of a Ministry of Health-approved clinical genetic laboratory offering gene sequencing, MLPA-based copy number analysis, NGS panels, pharmacogenetics, NIPT, clinical exome sequencing, and celiac disease genetic testing; (3) representation of international diagnostic technology companies (Centogene, Myriad Genetics, Labcorp, MRC-Holland, Sophia Genetics, Biocare Medical, and others) in Israel; and (4) international distribution of its own and partner products through a network of certified distributors across 16+ countries including Italy, Greece, Spain, Poland, France, and Uzbekistan.

The underlying technology stack combines Pronto's proprietary PRONTO ELISA platform with industry-standard methodologies including MLPA (via MRC-Holland's 400+ kit catalog), capture-based NGS panels (via Sophia Genetics' DDM platform and TWIST/CES exome panels covering approximately 4,900 disease-associated genes), and Centogene's CAP/CLIA-certified clinical exome sequencing for higher-complexity interpretation. The lab operates under ISO 9001:2015, EN46001, and ISO27799 certifications, with PRONTO kits carrying CE marking for European market access.

Pronto's revenue model is a hybrid of professional services (clinical genetic testing for hospitals, HMOs, pharmaceutical companies, private patients, and research institutions), one-time diagnostic kit sales (PRONTO® and distributed partner kits), and managed services/representation (commission-based technology distribution). Go-to-market is primarily enterprise field sales into Israeli healthcare institutions, supplemented by physician referrals, hospital partnerships, and an international distributor network. Pricing is not publicly disclosed; test turnaround times range from 4 weeks (celiac genetic testing) to 6–8 weeks for MLPA and most NGS panels. The company is led by founder/CEO Dr. Nir Navot, with laboratory direction under Sigal Tzvoni.

Name

Pronto Diagnostics

Legal name

פרונטו דיאגנוסטיקה בע"מ (Pronto Diagnostics Ltd.)

Website

https://prontodiagnostics.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Pronto Diagnostics is a privately held Israeli molecular diagnostics company operating a Ministry of Health-approved clinical genetic laboratory in Tel Aviv. It manufactures proprietary PRONTO® ELISA diagnostic kits, offers comprehensive genetic testing services to Israeli hospitals, HMOs, and pharma, and distributes international diagnostic technologies across 16+ countries.

Ownership category

akta.pro rank

Product category

Molecular Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Molecular diagnostics
• Genetic testing services
• Clinical laboratory services
• Diagnostic kit manufacturing
• Prenatal genetic screening

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: The company operates a Ministry of Health-approved clinical genetic laboratory providing genetic testing services to hospitals, health maintenance organizations, pharmaceutical companies, private customers, research organizations, and global customers. Services include gene sequencing, MLPA testing, NGS panels, pharmacogenetics, prenatal testing (NIPT), and clinical exome sequencing.
2. Diagnostic Kit Manufacturing and Sales: Manufacturing, development and marketing of PRONTO brand diagnostic kits based on proprietary ELISA technology for single nucleotide primer extension. Products have CE certification and meet strict quality manufacturing standards including ISO 9001:2015, EN46001, and ISO27799.
3. International Technology Representation: Representing leading international companies that developed advanced technologies for genetic laboratories. Pronto markets these technologies, implements them, and provides ongoing support to laboratories throughout the process.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Pronto Diagnostics develops, manufactures, and markets proprietary PRONTO® ELISA-based diagnostic kits for single nucleotide primer extension, and operates a Ministry of Health-approved clinical genetic laboratory providing comprehensive genetic testing services—including MLPA-based deletion/duplication analysis, NGS gene panels, pharmacogenetics, non-invasive prenatal testing (NIPT), and clinical exome sequencing—to hospitals, health maintenance organizations, pharmaceutical companies, research institutions, and private customers. The company also represents international diagnostic technology providers in Israel and distributes their kits.

Product overview

Pronto Diagnostics is a molecular diagnostics company operating in four areas: (1) Development, manufacturing, and marketing of proprietary PRONTO® diagnostic kits based on ELISA technology for genetic disease detection; (2) A Ministry of Health-approved clinical genetic laboratory offering comprehensive gene sequencing, MLPA analysis, and NGS panels; (3) Representation of international diagnostic companies in Israel; (4) Distribution of proprietary tests by sending samples to partner laboratories. The portfolio includes the PRONTO® diagnostic kit product line, genetic testing services with over 100+ NGS gene panels and pharmacogenetics tests, NIPT services via MaterniT Focus, clinical exome sequencing through CentoGene Germany, celiac disease genetic testing, and MLPA laboratory services. The company also distributes products from partner companies including MRC-Holland, Sophia Genetics, and others.

Differentiator

Problem solved

Functional benefit

Products and services

• PRONTO® Diagnostic Kits Proprietary diagnostic kits based on PRONTO® ELISA technology for detecting genetic diseases using a single nucleotide primer extension method. CE certified and manufactured in-house under ISO 9001:2015, EN46001, and ISO27799 standards.
• Genetic Testing Services Clinical genetic laboratory services offering comprehensive gene sequencing, MLPA-based detection of deletions and duplications, NGS panels, pharmacogenetics, and oncogenetics testing for conditions including breast cancer and colorectal cancer.
• MaterniT Focus (NIPT) Non-invasive prenatal testing (NIPT) that examines all chromosomes in the fetal genome, offered through the nipt.co.il platform.
• Clinical Exome Sequencing Genetic testing service analyzing thousands of genes simultaneously, performed at the CentoGene laboratory in Germany using TWIST exome and CES panels. Offers turnaround times of 30 business days (Gold) or 15 business days (Platinum) with CAP/CLIA certified quality standards and 98% of target bases covered at 10X depth.
• Celiac Disease Genetic Matching Test Genetic compatibility test for celiac disease that examines HLA gene combinations responsible for DQ2 and DQ8 formation; can exclude celiac disease with over 95% certainty, delivered from an ISO 9001:2015-certified, Ministry of Health-approved laboratory within 4 weeks.
• MLPA Laboratory Services MLPA (Multiplex Ligation-dependent Probe Amplification) laboratory offering prenatal and other gene testing for detecting deletions and duplications. Includes BRCA1/2 testing, FAP, HNPCC, SMA, DMD, and Y chromosome microdeletion testing for global customers.
• Pharmacogenetics Tests Personalized medication therapy testing including WarfaRisk (warfarin dosing), ThromboRisk (thrombosis predisposition), TamoxiRisk (tamoxifen response), IrinoRisk (irinotecan toxicity), ClopidoRisk (clopidogrel response), and 5FU sensitivity testing.

Quantifiable outcome

• 98% of target bases covered at 10X depth
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core.

• Atalev (1992) Ltd.coreChannel Partner/ Reseller/ DistributorDistributor for Uzbekistan market. Address: P.O. Box 1340, Kfar Saba, Israel. Contact: [email protected]
• Bouty S.p.A./Technogenetics S.r.L.coreChannel Partner/ Reseller/ DistributorItalian distributor for Pronto products. Address: Via della Filanda 30, I-26900 Lodi San Grato, Italy. Contact: [email protected]
• Varel as S.A.coreChannel Partner/ Reseller/ DistributorGreek distributor. Address: Eleftherias 4, 14564 Kifissia, Athens, Greece. Contact: [email protected]
• Diagnostica LongwoodcoreChannel Partner/ Reseller/ DistributorSpanish distributor. Address: Camino del Pilon 86, casa 7, 50011 Zaragoza, Spain. Contact: [email protected]
• S.G.S. International Trade 2001 Ltd.coreChannel Partner/ Reseller/ DistributorPolish distributor. Address: Jana Pawla 92 m 43, 09-410 Plock, Poland. Contact: [email protected]
• InGen BioSciencescoreChannel Partner/ Reseller/ DistributorFrench distributor. Address: Technopolis Bat 3, 17 avenue du Parc, 91380 Chilly-Mazarin, France. Contact: [email protected]
• CentogenecoreTechnology or IntegrationGlobal leader in genetic diagnostic testing for rare hereditary diseases with broad test portfolio covering over 2,300 genes, biochemical tests, biomarker and clinical whole exome sequencing and whole genome sequencing. Services over 100 countries worldwide. Pronto offers Centogene tests through its laboratory services.
• Myriad GeneticscoreTechnology or IntegrationProvider of myRisk Hereditary Cancer panel for 8 important cancers and EndoPredict multi-gene test for breast cancer patients. Available in both kit and service format.
• Laboratory Corporation of America (Labcorp)coreTechnology or IntegrationGlobal clinical laboratory providing diagnostic testing services. Serves managed care organizations, biopharmaceutical companies, governmental agencies, physicians and healthcare providers, hospitals, employers, patients, CROs, and independent clinical laboratories.
• MRC-HollandcoreTechnology or IntegrationOffers over 400 MLPA, digitalMLPA and Melt Assays based kits studying gene copy number variations associated with disease. Provides Coffalyser.Net free MLPA analysis software.
• Sophia GeneticscoreTechnology or IntegrationOffers capture-based NGS panels with Sophia DDM software-as-a-service platform for routine diagnostic testing. Integrates modules for analysis and protection of clinical NGS data.
• Centogene (CentoGene) GmbHcoreTechnology or IntegrationGerman laboratory partner for clinical exome sequencing. CAP/CLIA certified, Ministry of Health approved to receive samples from Israel. Provides services to over 100 countries. Uses CentoMD genetic variant database for clinical interpretation.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Centogene: Centogene is a global leader in rare disease genetic testing offering clinical exome sequencing, whole genome sequencing, and biochemical tests. It is both a core technology partner of Pronto and a directly comparable clinical genetic laboratory operating across 100+ countries.
• GeneDx: GeneDx (a subsidiary of Sema4) is a clinical genomics laboratory specializing in rare disease exome and genome sequencing — directly comparable to Pronto's clinical exome sequencing service.
• Ambry Genetics: Ambry Genetics is a clinical genetic testing laboratory specializing in hereditary cancer, rare disease exome sequencing, and pharmacogenetics — directly comparable to Pronto's clinical genetic testing portfolio.
• Invitae: Invitae operates a high-volume clinical genetic testing laboratory offering hereditary cancer, reproductive health, and rare disease panels. It competes in similar clinical genetic testing categories as Pronto.
• BioReference Laboratories: BioReference Laboratories (an OPKO Health subsidiary) provides specialty clinical diagnostics including reproductive genetics and hereditary cancer testing — directly comparable to Pronto's clinical genetic testing services.
• Myriad Genetics: Myriad is a major hereditary cancer and pharmacogenetics testing provider (myRisk Hereditary Cancer panel, EndoPredict). It is both a partner and a comparable peer given overlapping cancer predisposition and pharmacogenetics offerings.
• Sophia Genetics: Sophia Genetics offers capture-based NGS panels with the Sophia DDM SaaS platform for routine diagnostic testing — directly comparable to Pronto's NGS panel offering and the company's analytical/interpretation capability.

Broad incumbents

• Laboratory Corporation of America (Labcorp): Labcorp is a global clinical laboratory offering a broad menu including genetic and molecular diagnostics. It is both a partner and a broad incumbent whose genetic testing capabilities overlap with Pronto's clinical lab services.
• Quest Diagnostics: Quest Diagnostics is one of the largest US clinical laboratories offering reproductive genetics, hereditary cancer, and pharmacogenetics. It represents the broad-incumbent competitive threat in clinical genetic testing.

Emerging players

• MRC-Holland: MRC-Holland manufactures over 400 MLPA, digitalMLPA, and Melt Assay kits for gene copy number detection. It is both a core technology partner supplying Pronto's MLPA lab and a comparable specialty diagnostics manufacturer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pronto Diagnostics